Esperion Historical Cash Flow
| ESPR Stock | USD 1.73 0.09 4.95% |
Analysis of Esperion Therapeutics cash flow over time is an excellent tool to project Esperion Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 198 K or Other Non Cash Items of 57.9 M as it is a great indicator of Esperion Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Esperion Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Esperion Therapeutics is a good buy for the upcoming year.
Esperion |
About Esperion Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Esperion balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Esperion's non-liquid assets can be easily converted into cash.
Esperion Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Esperion Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.At this time, Esperion Therapeutics' Investments are relatively stable compared to the past year. As of 02/26/2025, Cash Flows Other Operating is likely to grow to about 52.2 M, though Change In Cash is likely to grow to (36.4 M).
Esperion Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Esperion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Esperion Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 137.9M | (46.1M) | (134.1M) | (42.5M) | (38.3M) | (36.4M) | |
| Free Cash Flow | (98.5M) | (263.8M) | (174.8M) | (135.5M) | (121.9M) | (115.8M) | |
| Change In Working Capital | (4.3M) | (52.5M) | (3.4M) | 13.7M | 12.3M | 12.9M | |
| Begin Period Cash Flow | 167.1M | 305.0M | 258.9M | 124.8M | 143.5M | 87.7M | |
| Other Cashflows From Financing Activities | (14.9M) | 49.5M | (58.2M) | (6.4M) | (7.4M) | (7.0M) | |
| Depreciation | 547K | 612K | 500K | 164K | 188.6K | 198.0K | |
| Other Non Cash Items | 33.8M | 35.5M | 46.5M | 48.0M | 55.2M | 57.9M | |
| Total Cash From Operating Activities | (85.2M) | (263.8M) | (174.8M) | (135.5M) | (121.9M) | (115.8M) | |
| Change To Account Receivables | (10.7M) | (10.5M) | (10.8M) | (14.8M) | (13.3M) | (12.6M) | |
| Net Income | (143.6M) | (269.1M) | (233.7M) | (209.2M) | (188.3M) | (178.9M) | |
| Total Cash From Financing Activities | 201.7M | 268.2M | 32.6M | 50.5M | 58.0M | 88.9M | |
| End Period Cash Flow | 305.0M | 258.9M | 124.8M | 82.2M | 94.6M | 94.6M | |
| Stock Based Compensation | 28.4M | 24.3M | 15.2M | 12.0M | 13.8M | 15.4M | |
| Total Cashflows From Investing Activities | 64.2M | 21.4M | (50.5M) | 8.1M | 9.3M | 9.8M | |
| Other Cashflows From Investing Activities | 65.2M | (12.5M) | (50.5M) | 8.1M | 9.3M | 11.5M | |
| Change To Liabilities | (6.1M) | 27.2M | (28.5M) | 9.6M | 11.1M | 6.6M | |
| Sale Purchase Of Stock | 11.8M | (55M) | 222.5M | 90.8M | 81.8M | 64.2M | |
| Investments | 34.7M | (50.5M) | 8.1M | 30.7M | 35.3M | 37.1M | |
| Cash And Cash Equivalents Changes | 130.1M | 137.9M | (46.1M) | (134.1M) | (120.7M) | (114.7M) | |
| Cash Flows Other Operating | 6.9M | 16.8M | 38.7M | 43.2M | 49.7M | 52.2M | |
| Change To Netincome | 25.9M | 28.4M | 21.7M | 15.2M | 17.5M | 18.7M | |
| Net Borrowings | (1.0M) | 280M | 225.6M | (440K) | (506K) | (480.7K) | |
| Change To Operating Activities | 6.6M | (10.7M) | 5.7M | 5.4M | 6.3M | 6.6M |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Esperion Stock
| 0.6 | OPT | Opthea Earnings Call Today | PairCorr |
| 0.56 | GANX | Gain Therapeutics | PairCorr |
| 0.56 | PHGE | Biomx Inc | PairCorr |
| 0.49 | CUE | Cue Biopharma | PairCorr |
| 0.49 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.